Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Cephalexin 250 mg Capsules in Healthy Volunteers
NCT02123446Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cefalexin in bacterial infection (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration Versus Time Curve of Cephalexin From Time Zero to Infinity at 7 hours. Started Apr 2014; status: completed.
02
Drugs
cefalexin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02123446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02123446.